What to Know About Stage 3 Non-Small Cell Lung Cancer

Johnson & Johnson Says Its Lung Cancer Drug Significantly Extended Survival

The standard option for many patients with non-small cell lung cancer today is AstraZeneca's targeted therapy Tagrisso. A year and a half ago, data showed this drug could provide patients with what Yale Cancer Center deputy director Roy Herbst at the time called an "extraordinary" 51% reduction in the risk of death. Now, scientists at Johnson & Johnson think they have a drug combination that can take survival for these patients even further.

The combination is a duo of two drugs from J&J and Janssen, Rybrevant and Lazcluze. In a Phase 3 clinical trial, patients who received the combo had longer overall survival than those who received Tagrisso alone, J&J announced in a press release on Tuesday. The full data from the study, called the MARIPOSA trial, are not yet published, but J&J officials told STAT it would soon be presented at an upcoming scientific meeting.

Beating Tagrisso in overall survival means the combo could have the potential to be a blockbuster drug and extend the lives of hundreds of thousands of patients. "We think this is going to be an absolute game changer and the future of the standard of care for patients with non-small cell lung cancer," said Biljana Naumovic, president of U.S. Oncology solid tumors at J&J.

STAT+ Exclusive Story

Already have an account? Log in

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Individual plans Group plans View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Non-Small Cell Lung Cancer

Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence (AI) in oncology, while cautioning against its limitations, including the risk of unsupported recommendations.

A New Turning Point In Lung Cancer Treatment, Inspired By Mussels

Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for lung cancer, leveraging mucoadhesive protein nanoparticles inspired by the adhesive properties of marine mussels. This effort was spearheaded by Professor Hyung Joon Cha (Department of Chemical Engineering and Graduate School of Convergence Science and Technology with a specialization in Medical Science) and Dr. Yeonsu Jeong (Department of Chemical Engineering) at POSTECH, in collaboration with Professor Yun Kee Jo (Department of Biomedical Convergence Science and Technology, Advanced Institute of Science and Technology) at Kyungpook National University.

Lung cancer remains one of the deadliest cancers globally. Non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, is particularly challenging to treat due to difficulties in early detection. Current anticancer treatments are predominantly administered intravenously, impacting both malignant and healthy tissues, often leading to severe adverse effects. As a result, inhalable therapeutics have emerged as a promising alternative, enabling localized drug delivery directly to the lungs. However, the efficacy of this approach has been significantly hindered by the lung's mucosal barriers and immune cells. Building on this context, collaborative research has culminated in the development of a mucoadhesive protein nanoparticle designed for lung cancer treatment.

This approach leverages the remarkable adhesive properties of marine mussel proteins, renowned for their underwater adhesion. Drawing inspiration from the oxidation-reduction mechanisms of foot protein type 6 (fp-6), the researchers engineered foot protein type 1 (fp-1) by integrating cysteine, creating a biomaterial with enhanced adhesive strength and precise drug delivery capabilities within the lung cancer microenvironment. These nanoparticles exhibit exceptional therapeutic efficacy by enabling selective payload release while effectively inhibiting release in healthy tissues to minimize adverse effects. Moreover, the intrinsic biocompatibility, biodegradability, and immunocompatibility of marine mussel proteins ensure superior biological safety and substantially prolong the retention of anticancer drugs, thereby amplifying their therapeutic impact.

In animal models of lung cancer, the nanoparticles developed by the research team and their contained anti-cancer drugs showed effectiveness in inhibiting cancer cell metastasis and invasion after being delivered to the lungs through a nebulizerand adhering to the mucosa for extended periods. This advancement holds the potential to enhance patient access to lung cancer treatment, as the simplified inhalation-based drug administration could be self-managed at home. Furthermore, this approach may significantly improve patients' quality of life by reducing the need for hospital visits.

Professor Hyung Joon Cha, who spearheaded the collaborative research at POSTECH, stated, "The findings from our study have the potential to substantially enhance both the precision and efficacy of lung cancer treatments, while significantly improving patients' quality of life."

The research findings were published online in Biomaterials, the premier international journal for biomaterial research. This study was made possible through funding from the National Research Foundation (NRF) Mid-Career Researcher Program, the Ministry of Health and Welfare's Dental and Medical Technology R&D Program, and the Pan-Governmental Regenerative Medicine Technology Development Program.

---